- Home
- LYEL vs BVS Comparison
LYEL vs BVS Comparison
Compare LYEL & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYEL | BVS |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 482.9M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | LYEL | BVS |
|---|---|---|
| Price | $25.74 | $8.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $25.00 | $14.25 |
| AVG Volume (30 Days) | 91.2K | ★ 293.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 163.46 |
| EPS | N/A | ★ 0.33 |
| Revenue | $61,000.00 | ★ $568,087,000.00 |
| Revenue This Year | N/A | $7.42 |
| Revenue Next Year | N/A | $6.46 |
| P/E Ratio | ★ N/A | $25.41 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $5.81 |
| 52 Week High | $45.00 | $11.25 |
Technical Indicators
Market Signals| Indicator | LYEL | BVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 56.72 |
| Support Level | $21.27 | $6.42 |
| Resistance Level | $27.30 | $9.01 |
| Average True Range (ATR) | 1.78 | 0.39 |
| MACD | 0.32 | -0.02 |
| Stochastic Oscillator | 73.27 | 46.67 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About BVS Bioventus Inc.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.